NEW YORK – MilliporeSigma said this week that it has acquired BSSN Software, a laboratory informatics company based in Darmstadt, Germany. BSSN's employees have joined MilliporeSigma as part of its applied digital lab productivity solutions team. Financial terms of the deal were not disclosed.
The acquisition will allow MilliporeSigma's customers to better use and share their scientific data, the company said, adding that it acquired BSSN primarily for its lab data management and integration software, which unifies data from instruments and data systems and makes them available for analyzing, processing, and sharing.
In a recent filing with the US Securities and Exchange Commission, Illumina disclosed details of its deconsolidation of Helix. According to a form 10-Q filed July 31, Illumina amended its long-term supply and license agreements with Helix, including discounted supply terms. Illumina also noted that it absorbed 50 percent of Helix's losses for the three months ended June 30.
As part of the agreement, Helix repurchased all outstanding equity interests previously issued to Illumina in exchange for a contingent value right (CVR), a type of financial instrument that gives the seller an option to purchase additional shares if a specific event occurs. Illumina recorded this CVR at a fair value of $30 million. The CVR has a term of seven years.
Adaptive Biotechnologies announced this week that it has signed a 12-year lease with Alexandria Real Estate Equities for a 100,000-square-foot building in Seattle. The building will serve to expand the company's lab capacity, R&D footprint, and office space, Adaptive said. Adaptive expects the building — which will be part of Alexandria's Eastlake Life Science Campus in the Lake Union neighborhood and close to the immune sequencing firm's current headquarters — to be completed in 2020, and plans to move in by 2021.
Curetis announced this week that its wholly owned subsidiary Ares Genetics GmbH has opened a specialized service laboratory offering next-generation molecular antimicrobial resistance testing services, with an initial focus on infection control, AMR epidemiology and surveillance, clinical research, and pharmaceutical anti-infectives R&D. The newly opened lab is located at the Vienna Biocenter Campus in Vienna, Austria, and will serve researchers, hospitals, public health institutions, and pharmaceutical companies, Curetis said.
Cancer diagnostics firm Celcuity this week said that its net loss for the second quarter narrowed to $1.7 million, or $.17 per share, from $1.8 million, or $.18 per share, a year ago. The Minneapolis-based firm reported no revenues, the same as in Q2 2018.
Its R&D costs were relatively flat year over year at $1.5 million, while its general and administrative costs were trimmed 3 percent to $371,988 from $382,646.
Celcuity finished the quarter with $14.9 million in cash and cash equivalents. Celcuity is a cellular analysis firm developing diagnostics to improve the clinical outcomes of patients being treated with targeted therapies. Its CELx platform uses a patient's living tumor cells to identify abnormal cellular activity driving the patient's cancer and the most appropriate therapy.
Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.